Isolated Cholestatic Liver Injury? Consider Metastatic Liver Injury

Alexis Espinal, BS¹, Jonathan Li, MD², Rawal Rachna, MD³
¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²Combined Internal Medicine-Pediatrics Residency Program, UPMC, Pittsburgh, PA, ³Department of General Internal Medicine, UPMC, Pittsburgh, PA

Learning Objectives
- To recognize an uncommon clinical presentation of metastatic small cell lung cancer (SCLC) and general disease course.
- To recognize differences between modalities of imaging available for evaluating hepatobiliary disease.
- To recognize availability bias when encountering a common illness script of abdominal pain and abnormal LFTs.

Case Presentation
71-year-old female with 30-pack-year smoking history and hypothyroidism presenting for one week of severe, stabbing, intermittent right upper quadrant pain with one month of decreased appetite. Pain is not associated with eating or stooling. ROS negative for fevers/chills, nausea, vomiting, diarrhea, constipation, or B symptoms.

Hospital Course

Notable Labs
- CMP: ALT 64, AST 162, Alk Phos 916, Tbili 5.0, Cr 2.0
- CBC: WBC 10.9 (normal differential), Hgb 16.4, PLT 394
- Lactate 2.9
- CRP 15.7, ESR 21
- Negative blood and urine cultures
- Negative hepatitis and HIV serologies
- Negative AFP, CEA, CA 19-9

Physical Exam
- Vitals: 37C, 128 bpm, 119/89 mm Hg, and 97% room air
- Abdomen: RUQ tenderness, + Murphy Sign, no hepatomegaly

Abdominal U/S: Evidence of hepatic fibrosis (Fig 1)
CT Abdomen and Pelvis: Heterogenous liver parenchyma with left sided focal hypoattenuation concerning for infiltrative process (Fig 1)
CT Angiogram Chest: Bulky mediastinal adenopathy, bulky left hilar lymphadenopathy with left bronchial narrowing - cannot exclude left hilar mass.
MRI: Heterogenous liver parenchyma suggesting hepatic fibrosis and/or infiltrative process (Fig 1)
FDG PET Imaging: Markedly enlarged liver with diffuse hepatic metastasis, multiple osseous metastasis, and left hilar lung mass with significant mediastinal lymphadenopathy. (Fig 1 & 2)

Outcome
Given the histopathological changes (Fig 2) in combination with tumor phenotype indicating a poorly differentiated neuroendocrine carcinoma, our patient was ultimately diagnosed with primary SCLC. Her ALP and T-bili doubled in 2 weeks and had 5 lbs of weight loss. Unfortunately, she rapidly declined and was transitioned to comfort care.

Conclusions
- Cholestatic injury is not always due to a local process, beware of availability bias.
- ~15% of all lung cancers are SCLC of which 60% present with metastatic disease, most commonly brain, liver, adrenals, bone/bone marrow.
- Rapid symptom onset ~ 8-12 weeks before presentation.
- Untreated, median survival is 2-4 months.
- A number of reports describe isolated cholestatic liver injury as the presenting sign of metastatic SCLC.
- Clinicians should have high suspicion for metastatic SCLC in patients with both a pulmonary mass and infiltrative liver disease.

References

Figure 1: Hepatic imaging with US, CT, MRI, and PET
Figure 2: Hepatic imaging with PET-CT and histology suggesting neuroendocrine carcinoma